Health Care

Shares of Sartorius AG climb after Exane BNP Paribas upgrades it to Outperform, citing resilient supply chains and a strong med‑tech pipeline.

Explore Fresenius SE & Co KGaA’s dialysis‑heavy strengths, regulatory pressures, and growth chances in tele‑dialysis and digital health—insights for investors and analysts.

Explore how Bayer AG’s partnership with DCM Shriram, glyphosate‑study fallout, and Leverkusen’s Champions League win shape investor outlook and growth strategy.

Pfizer cuts Swiss staff, sees cost savings, boosts margins; phase‑III study shows Tukysa extends survival for HER2‑positive breast cancer, while a new GLP‑1 partnership targets fast‑track obesity treatment.

Explore how Novo Nordisk’s purchase of Akero Therapeutics boosts its pipeline, beats patent pressures, and strengthens market position beyond diabetes.

Fresenius Medical Care’s new Global Chief Medical Officer signals a strategic pivot toward value‑based dialysis, boosting tech investment, governance, and market share.

Grifols SA’s split analyst outlook: a major bank cuts its target while a sovereign wealth fund ups its stake—find out how plasma‑derived drug pressures, R&D bets and diagnostics growth could shape its future.

Fisher & Paykel’s December 2024 update shows strong dividend performance, stable portfolio weight in Kingfish, and unchanged quality compliance, confirming its role as a reliable respiratory‑care provider.

IQVIA refines debt, cuts interest, and faces Belgian regulatory probe—boosting margins and market‑access plans while navigating competition scrutiny.

Zimmer Biomet’s 17% share drop reflects modest growth, tighter reimbursement and rising costs—yet untapped MIS, emerging markets, and sustainability could reverse the trend.